Business
Halozyme Therapeutics licenses drug-delivery technology and develops therapies.
Halozyme Therapeutics grew revenue, remained profitable, generated positive free cash flow at a 33.6% operating margin. The latest year combined rapid growth with high margins and strong free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 37.6%OK
- Profitability — Net income declined 28.6% to $316.889M from $444.091MWatch
- Cash flow — Free cash flow grew 37.6% to $644.588M from $468.368MOK
- Margins — Operating margin contracted 2074 bps to 33.58%Watch
- Accounting — The latest year combined rapid growth with high margins and strong free cash flowNote
- Insiders — 0 purchases and 43 salesWatch
Where the revenue comes from
Fiscal 2025, as HALOZYME THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Royalties$867.8M
- Product sales, net$376.4M
- Revenues under collaborative agreements$152.3M
Leadership changes
From HALOZYME THERAPEUTICS, INC.'s own filings, the day they're filed.
- Darren Snellgrove · Chief Financial Officer · appointmenteff. 2026-06-08
- David Ramsay · CFO · appointmenteff. 2026-06-08
- David Ramsay · Chief Financial Officer · appointmenteff. 2026-03-23
Latest filings
- 8-K · Company announcement2026-08-18
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-02
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about HALOZYME THERAPEUTICS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.